A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Alzheimer's Type Dementia Clinical Trial

Official title:
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Status Completed

Clinical Trial Summary

The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01404169
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	September 2011
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01972204` - Intensive Instruction on the Use of Aricept	N/A
Recruiting	`NCT05397639` - Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Phase 3
Completed	`NCT01539031` - Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease	Phase 3
Completed	`NCT01276353` - A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia	Phase 2
Completed	`NCT03732053` - The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients	N/A
Terminated	`NCT02020356` - Music Therapy in Alzheimer's Disease	N/A